Literature DB >> 3090097

The changing ratio of serum bioactive to immunoreactive follicle-stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone antagonist.

K D Dahl, S N Pavlou, W J Kovacs, A J Hsueh.   

Abstract

Using a recently developed granulosa cell aromatase bioassay (GAB), we measured serum bioactive follicle-stimulating hormone (bio-FSH) levels in 5 normal men after administration of a potent GnRH antagonist. Although only minimal suppression of immunoreactive FSH (immuno-FSH) was detected during administration of 20 mg of the antagonist, [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-h(Arg(Et2)6,D-Ala10]GnRH , pronounced inhibition (79 to 89%) of bio-FSH levels occurred. Concomitantly, the ratio of bio- to immuno-FSH levels dramatically decreased within 6 h after antagonist administration. These data reinforce earlier expectations that GnRH antagonists might be potential male contraceptives and provide the first report of changes in circulating bio- to immuno-FSH levels. The GAB assay will facilitate future studies on the biochemical mechanisms by which GnRH antagonists induce changes in the bioactivity of circulating FSH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090097     DOI: 10.1210/jcem-63-3-792

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  In vitro bioassays of follicle-stimulating hormone: methods and clinical applications.

Authors:  M Simoni; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

2.  Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.

Authors:  T J Gelety; E S Surrey
Journal:  J Assist Reprod Genet       Date:  1997-10       Impact factor: 3.412

3.  Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.

Authors:  M C Edelstein; R G Brzyski; G S Jones; S Oehninger; S M Sieg; S J Muasher
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-06

4.  Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

Authors:  R Felberbaum; T Reissmann; W Küpker; S Al-Hasani; O Bauer; T Schill; C Zoll; C Diedrich; K Diedrich
Journal:  J Assist Reprod Genet       Date:  1996-03       Impact factor: 3.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.